EPRX (Eupraxia Pharmaceuticals Inc.) Short-Term Debt to Capital

Corporate company logo of Eupraxia Pharmaceuticals, Inc. (EPRX)

The specifics of Eupraxia Pharmaceuticals (EPRX) rely on strict adherence to transportation conditions for long-acting agents to ensure patient safety. The company is currently facing a liquidity shortage and the depletion of reserves due to R&D expenses, which makes the 0.00 metric significant. Meanwhile, the implementation of sustained-release methods helps extend the relevance of its products. The asset's price trajectory on GURU.Markets clearly illustrates the company's current market dynamics.

Ratio of Short-Term Indebtedness to Capital: eupraxiapharma.com (EPRX) for 04/06/2024 - 11/01/2026

Analytical breakdowns for Eupraxia Pharmaceuticals

- stock quotes and analyst forecast:
Stock Price Eupraxia Pharmaceuticals|EPRX - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Eupraxia Pharmaceuticals, Inc.|EPRX - Enterprise Value
- book capitalization information:
Net Assets per Single Share Eupraxia Pharmaceuticals|EPRX - Accounting Value of Company|Market Value to Book Value Ratio eupraxiapharma.com|EPRX - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Eupraxia Pharmaceuticals|EPRX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Eupraxia Pharmaceuticals|EPRX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Eupraxia Pharmaceuticals, Inc.|EPRX - Long-Term Debt|Company Current Liabilities Eupraxia Pharmaceuticals|Quick Ratio eupraxiapharma.com
- company profitability and valuation multiples indicators:
EPRX - Final Profit
Fundamental valuation:EPRX Eupraxia Pharmaceuticals Inc.
Brand item of eupraxiapharma.com

Eupraxia Pharmaceuticals focuses on creating innovative analgesic delivery systems for the treatment of osteoarthritis. The ratio of short-term liabilities to equity reflects the proportion of borrowed capital with a maturity of more than one year within the financing structure. An increase in this ratio signals rising debt leverage and liquidity risks as the company prepares for drug commercialization. By analyzing the history of short-term loans to equity, an investor can assess the issuer's financial stability.

Competitors of Eupraxia Pharmaceuticals (EPRX)

Short-Term Debt to Capital HLN|KVUE (Kenvue Health) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VRNA (Verona Pharma plc)|Short-Term Debt to Capital jyongbio.com MENS|LGND - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital AMRX (Amneal Pharmaceuticals, Inc.)|Perrigo Company (PRGO) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Alvotech Biopharmaceuticals|LQDA (Liquidia Corporation) - Short-Term Debt to Capital|Short-Term Debt to Capital glpg.com|Short-Term Debt to Equity Ratio ANIP (ANI Pharmaceuticals, Inc.)|MNKD (MannKind Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Amphastar AMPH|Pacira Corp (PCRX) - Current Liabilities to Capital|SPRY: Short-Term Debt to Equity Ratio|theravance.com - Short-Term Loans to Capital Ratio|AQST: Short-Term Debt to Capital|scPharmaceuticals - Ratio of Short-Term Indebtedness to Capital|TECX (Tectonic Therapeutic Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Tonix Pharmaceuticals Holding TNXP|Short-Term Debt to Equity China SXT Pharmaceuticals (SXTC)|BHST (bioharvest.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital EXOZ (eXoZymes)|Oramed (ORMP) - Current Liabilities to Capital|ENTX: Short-Term Debt to Equity Ratio|HYFT - Short-Term Debt to Capital|ABVC BioPharma (ABVC) - Short-Term Debt to Equity|Current Liabilities to Equity CPIX (cumberlandpharma.com)|Short-Term Debt to Equity Quantum BioPharma|FGEN: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital TELO|Short-Term Debt to Capital ranitherapeutics.com (RANI)|Synergy CHC - Short-Term Debt to Equity Ratio|RLYB: Short-Term Debt to Capital Ratio|Lexaria - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Pulmatrix Inc PULM|PTHL: Short-Term Debt to Capital|Aptorum Group (APM) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio LYRA|IBO: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity TNF Pharmaceuticals (TNFA)|YCBD: Current Liabilities to Equity|Short-Term Debt to Capital PRFX (PainReform Limited)|Ratio of Short-Term Indebtedness to Capital CYTO|Lipella Pharmaceuticals - Short-Term Debt to Capital|OPTN - Short-Term Debt to Capital|Pieris Pharmaceuticals, Inc. (PIRS) - Short-Term Debt to Equity|Procaps Group - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Petros|Short-Term Debt to Equity Ratio Qilian International Corp (QLI)|Short-Term Debt to Capital SLRN|Short-Term Debt to Capital tffpharma.com (TFFP)